# Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

> **NCT00980395** · PHASE2 · COMPLETED · sponsor: **University of Arizona** · enrollment: 24 (actual)

## Conditions studied

- Lymphoma
- Mantle Cell Lymphoma
- Indolent Lymphoma
- SLL

## Interventions

- **DRUG:** rituximab
- **DRUG:** bortezomib
- **DRUG:** cladribine

## Key facts

- **NCT ID:** NCT00980395
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-07
- **Primary completion:** 2014-09-12
- **Final completion:** 2018-08-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00980395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00980395, "Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00980395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*